The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Key facts

Sponsor

Peking University People's Hospital

Principal Investigator

Qian Jiang, MD

Peking University People's Hospital

Intervention

Ponatinib(drug)

Enrollment

30 target

Eligibility

18 years · All sexes

Timeline

2024 – 2027

Study locations (15)

• Peking university people's hospital, Beijing, Beijing Municipality, China
• Beijing Lu Daopei Hospital, Beijing, China
• Chuiyangliu hospital affiliated to tsinghua university, Beijing, China
• Sichuan Provincial People's Hospital, Chengdu, China
• Nanfang Hospital, Southern Medical University, Guangdong, China
• The First Affiliated Hospital of Kunming Medical University, Kunming, China
• The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
• The First Affiliated Hospital of Guangxi Medical University, Nanning, China
• Nanyang Central Hospital, Nanyang, China
• Ningbo Medical Center Lihuili Hospital, Ningbo, China
• Qilu Hospital of Shandong University, Qilu, China
• Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Tianjin, China
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Henan Cancer Hospital, Wuhan, China
• Xi'an International Medical Center Hospital, Xi'an, China
• The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China

Collaborators

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Henan Cancer Hospital · Zhejiang University · Peking Union Medical College · Nanfang Hospital, Southern Medical University · Beijing Chuiyangliu Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Congenital generalized lipodystrophy

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT06092879
  Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
  Novartis Pharmaceuticals
• RECRUITINGNCT05682924
  Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
  Samara State Medical University
• RECRUITINGNCT05282108
  Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
  Hikma Pharmaceuticals LLC
• RECRUITINGPHASE2NCT05143840
  Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
  Augusta University
• RECRUITINGPHASE1, PHASE2NCT04925479
  Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
  Novartis Pharmaceuticals
• ACTIVE NOT RECRUITINGPHASE2NCT04626024
  Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
  Baylor College of Medicine
• RECRUITINGPHASE1, PHASE2NCT03934372
  Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
  Incyte Biosciences International Sàrl
• ACTIVE NOT RECRUITINGPHASE2NCT03516279
  Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
  ECOG-ACRIN Cancer Research Group

See all trials for Congenital generalized lipodystrophy →